New insulin pump software aims to cut dangerous low blood sugar events

NCT ID NCT05014789

Completed Disease control Sponsor: Tandem Diabetes Care, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an updated version of the Control-IQ system, which automatically adjusts insulin delivery for people with type 1 diabetes. Sixty-six adults and adolescents used the new software along with a continuous glucose monitor for several weeks. The main goal was to see if the improvements could reduce dangerously low blood sugar levels and prevent severe hypoglycemia and diabetic ketoacidosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Control-IQ technology 2.0 (a software update for the t:slim X2 insulin pump) used with the Dexcom G6 continuous glucose monitor
What this could lead to: If successful, this could lead to a safer, more effective automated insulin delivery system that reduces the risk of severe low blood sugar in people with type 1 diabetes.
What could go wrong: This is a small, early feasibility study (66 participants) testing planned improvements, not a final product. The results may not apply to all users, and the technology could still have safety issues or fail to perform as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1

Contacts and locations

Locations

University of Virginia

Charlottesville, Virginia, 22904, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.